Bögler Oliver, Mikkelsen Tom
William and Karen Davidson Laboratory of Brain Tumor Biology, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, Michigan 48202, USA.
J Cell Biochem. 2005 Sep 1;96(1):16-24. doi: 10.1002/jcb.20475.
New therapies for gliomas are urgently needed in view of the very marginal increase in patient survival that has been achieved over the past two decades, which is only somewhat mitigated by improvements in quality of life. Two relatively recent fields of research that hold out great promise in this area, are angiogenesis and apoptosis. Depriving growing tumors of the blood supply they need, or tipping the balance in the cancer cell towards cell death, both provide conceptually elegant approaches to therapy, with the hope of great efficacy and little toxicity. However, attempts at successfully translating exciting laboratory findings to the clinic have been slowed by the complexity of the underlying biology. In this article we examine some of the issues that have impeded progress, and examine the potential role that integrins may play as targets, with a role in both angiogenesis and apoptosis.
鉴于在过去二十年中患者生存率仅有非常有限的提高，且仅在一定程度上因生活质量的改善而有所缓解，因此迫切需要针对神经胶质瘤的新疗法。在这一领域，两个相对较新的研究方向——血管生成和细胞凋亡——展现出了巨大的前景。切断生长中的肿瘤所需的血液供应，或者使癌细胞的平衡向细胞死亡倾斜，这两种方法在理论上都为治疗提供了巧妙的途径，有望实现高效低毒。然而，将令人兴奋的实验室研究成果成功转化到临床应用的尝试因基础生物学的复杂性而放缓。在本文中，我们探讨了一些阻碍进展的问题，并研究了整合素作为靶点在血管生成和细胞凋亡中可能发挥的潜在作用。
